A 3-month comparison of efficacy and safety of brimonidine-tartrate 0.2% timolol 0.5% fixed combination (BID) with timolol 0.5% (BID) or brimonidine-tartrate 0.2% (TID)

被引：0

作者：

Craven, ER

Choplin, N

Larsen, C

Olson, M

Whitcup, S

机构：

[1] Glacoma Consultants Colorado, Littleton, CO USA

[2] Eye Care San Diego, San Diego, CA USA

[3] Allergan Pharmaceut Inc, Irvine, CA USA

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2002年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

282

引用

页码：U54 / U54

页数：1

共 50 条

[21] Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension
LeBlanc, RP
OPHTHALMOLOGY, 1998, 105 (10) : 1960 - 1967
[22] Long-term efficacy and safety studies of brimonidine 0.2% compared with timolol 0.5% in patients with glaucoma and ocular hypertension
Melamed, S
VISION RESEARCH, 1996, 36 : 2313 - 2313
[23] A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma
Gómez-Aguayo F.
Paczka J.A.
Leñero-Córdova R.
Jiménez-Román J.
Davila-Villarreal J.
Hartleben C.
Baiza-Durán L.
Olvera-Montaño O.
García-Velez F.
Muñoz-Villegas P.
Ophthalmology and Therapy, 2018, 7 (1) : 145 - 156
[24] 12-month efficacy and safety of brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution in Korean patients with primary open-angle and normal-tension glaucomas-The KOCO Study
Park, Sang Woo
Park, Ki Ho
Kim, Joon Mo
Lee, Ji Woong
Lee, Youkyung
Maglambayan, Joy
Simonyi, Susan
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
[25] A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension
Mundorf, T
Williams, R
Whitcup, S
Felix, C
Batoosingh, A
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2003, 19 (01) : 37 - 44
[26] Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients
Kim, Joon Mo
Kim, Tae-Woo
Kim, Chan Yun
Kim, Hwang Ki
Park, Ki Ho
JAPANESE JOURNAL OF OPHTHALMOLOGY, 2016, 60 (01) : 20 - 26
[27] Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients
Joon Mo Kim
Tae-Woo Kim
Chan Yun Kim
Hwang Ki Kim
Ki Ho Park
Japanese Journal of Ophthalmology, 2016, 60 : 20 - 26
[28] Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma
Öztürk, F
Ermis, SS
Inan, UU
Asagidag, A
Yaman, S
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2005, 21 (01) : 68 - 74
[29] COMPARISON OF A FIXED COMBINATION OF DORZOLAMIDE AND TIMOLOL (BID) TO CONCOMITANT ADMINISTRATION OF DORZOLAMIDE (TID) PLUS TIMOLOL (BID) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA FOR 3 MONTHS
CLINESCHMIDT, CM
STRAHLMAN, ER
ANDERSON, K
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1995, 36 (04) : S736 - S736
[30] Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure - A 3-month comparison of efficacy, tolerability, and patient-reported measures
Solish, AM
DeLucca, PT
Cassel, DA
Kolodny, AH
Hustad, CM
Skobieranda, F
JOURNAL OF GLAUCOMA, 2004, 13 (02) : 149 - 157

← 1 2 3 4 5 →